No Data
No Data
Heyuan Biotech (688238.SH) announced its 2023 annual results, with a net loss of 128 million yuan, changing from profit to loss over the previous year
Heyuan Biotech (688238.SH) disclosed its 2023 annual report, and the company achieved revenue of 2 in 2023...
5.2 million restricted shares of Heyuan Biotech (688238.SH) will be listed and circulated on March 22
Heyuan Biotech (688238.SH) announced that the total number of shares in circulation in the company's current stock listing is 5.2 million shares, which are listed and in circulation...
Heyuan Biotech (688238.SH): The first phase of the employee stock ownership plan will raise no more than 50 million yuan
On February 7, Gelonghui (688238.SH) announced the first phase of the employee stock ownership plan. The total amount of self-financing funds raised by employees in the employee stock ownership plan was no more than 30 million yuan, which was a ratio of 6:4 with the incentive fund withdrawn by the company. The amount of incentive funds withdrawn by the company according to the “Remuneration Management System” did not exceed RMB 20 million. The total amount of capital to be raised in this employee stock ownership plan is not more than RMB 50 million. Using “shares” as the subscription unit, each share is 1 yuan, and the total subscription share is no more than 50 million shares. The specific share is determined based on the actual amount of funding contributions.
Heyuan Biotech (688238): CDMO business is under pressure and capacity utilization is expected to increase
The company predicts a net loss of 113-129 million yuan in 2023 The company issued a performance forecast: in 2023, revenue of 2.02-224 million yuan, a year-on-year decrease of 23-31%, and a net loss of 1.13-1.2 million yuan to the mother
Heyuan Biotech (688238.SH): Expected net loss of 113 million yuan to 129 million yuan in 2023
On January 29, Gelonghui (688238.SH) announced that according to preliminary estimates by the finance department, it is expected to achieve operating income of 20.200 million yuan to 224 million yuan in 2023, a decrease of 67.3043 million yuan to 89.03 million yuan over the same period last year, a year-on-year decrease of 23% to 31%. The company expects to achieve net profit attributable to owners of the parent company in 2023 compared with the same period last year, from -129.00 million yuan to -11.30 million yuan, a decrease of 15,202.52 from the same period last year
Heyuan Biotech (688238.SH): Currently, there are more than 280 cooperative CDMO projects in China
On December 14, Heyuan Biotech (688238.SH) said on an interactive platform that, as a leading domestic company that lays out gene and cell therapy, Heyuan Biotech has accumulated rich project experience in gene and cell therapy drug development with a large number of product development experience, advanced processes and production capacity, a high standard quality system, and a high-level technical service team, and has accumulated rich project experience in gene and cell therapy drug development, providing high-quality CRO/CDMO services for new drug projects in various fields such as oncolytic viruses, adenoviruses, lentiviruses, mRNA plasmids, CART, stem cells, NK cells, etc. Currently, domestic cooperation in CDM has accumulated
No Data